Editorial
|
|
|
Think in terms of the INN : one key to optimising use of drugs
|
|
|
Marketing Authorisations
|
|
|
In psoriatic rheumatism: too many risks, too little efficacy
|
|
|
|
|
|
No real simplification of anticoagulant therapy
|
|
|
|
|
|
|
Prevention of bipolar disorder: unconvincing trials
|
|
|
|
|
|
In post-transplant rejection: no better than sirolimus
|
|
|
|
|
|
In primary axillary hyperhydrosis: after local antiperspirant therapy and before surgery
|
|
|
|
|
|
In breast cancer patients with bone metastases: just another injectable bisphosphonate
|
|
|
Adverse Effects
|
|
|
Hasty approval jeopardises patient safety
|
|
|
|
|
|
|
UK agency warns against use of venlafaxine in patients with heart diseases, electrolyte disturbances or hypertension
|
|
|
|
|
|
Too many risks, and efficacy no better than paracetamol alone
|
|
|
|
|
|
Thinking about the role of NSAIDs may help
|
|
|
|
|
|
Should be restricted to precisely defined severe sepsis
|
|
|
Reviews
|
|
|
|
|
Aspirin alone prevents around 5 deaths per 1000 treated patients. Low-dose unfractionated heparin is combined with aspirin only in special situations. Thrombolytic therapy is controversial. Antihypertensive drugs seem justified in some cases.
|
|
|
Outlook
|
|
|
|
|
Physicians should participate in independent training programmes, and
|
|
|
|
|
|
|
|
|
Reliable information is rarely presented despite legal obligations; benefits are overstated and risks are minimized
|
|
|
|
|
|
Combinations with combined disadvantages
|
|
|
|
Forum
|
|
|
We need guidelines based on strong evidence
|
|
|
|
|
|
No major safety problem has been reported
|
|
|